NCT03268226View on ClinicalTrials.gov

Functional Respiratory Imaging Study (FRI)

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

January 30, 2019

Study Completion Date

January 30, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)

Trial Locations (5)

Unknown

SGS CPU Antwerpen, Antwerp

AZ Saint-Maarten, Duffel

Centre medical Erpent - Residence, Erpent

Heilige Familie AZ, Reet

National Koranyi Institute for TB and Pulmonology, Budapest

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03268226 - Functional Respiratory Imaging Study (FRI) | Biotech Hunter | Biotech Hunter